Biogen reports positive data of daclizumab over interferon beta-1a im to treat multiple sclerosis

Global biotechnology company Biogen has reported new data that demonstrates daclizumab’s positive cognitive outcomes, targeted and reversible mechanism of action (MOA), and safety profile over interferon beta-1a im in relapsing-remitting multiple scl…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news